NASDAQ · COCH
Healthcare · Medical - Devices
$6.81
Down-$0.14 (-2.01%)
Updated Nov 13, 2026, 1:13 PM
SID Score
5.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · COCH
1M range · 0 trading sessions · Daily adjusted prices
COCH does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning COCH.
Company
Market Activity
Research & News
COCH research
Company profile and research snapshot.
Envoy Medical Inc is a hearing health company focused on providing medical technologies. It is dedicated to pushing hearing technology beyond the status quo to provide patients with improved access, usability, independence and quality of life. The Company has one reportable segment: hearing. The hearing segment derives revenue from the sale of the Esteem FI-AMEI implants and replacement components to Esteem FI-AMEI implants.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 9, 2026 | HC Wainwright & Co. | Buy | — |
| Oct 27, 2026 | Lake Street | Buy | — |
| Oct 6, 2026 | Lake Street | Buy | — |
| Aug 21, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 27, 2026 | LUCID CAPITAL MARKETS | Buy | — |
No generated briefing is available yet.
Benzinga · Nov 5, 2026
Envoy Medical (NASDAQ:COCH) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs.
Benzinga · Nov 5, 2026
Envoy Medical (NASDAQ:COCH) reported quarterly losses of $(0.50) per share which beat the analyst consensus estimate of $(0.67) by 25.37 percent. This is a 42.86 percent decrease over losses of $(0.35) per share from
Benzinga · Oct 22, 2026
Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical" or the "Company"), a hearing health and neuroprosthetics company pioneering fully implanted hearing solutions, today announced that it will implement a
Benzinga · Oct 20, 2026
Company Believes It Is the First to Reach This Milestone in a U.S. Pivotal Trial of a Fully Implanted Cochlear ImplantRemains on Track to Reach 12-Month Visit Milestone by Early Q2 2027 and Submit Final Clinical PMA
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning COCH.
